William Blair upgraded Zealand Pharma (ZLDPF) to Outperform from Market Perform without a price target The firm sees the recent share pullback as creating a more favorable risk/reward profile given its “bull stance” on Amylin.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand Pharma upgraded to Outperform from Market Perform at William Blair
- Zealand Pharma removed from European Conviction List at Goldman Sachs
- Zealand Pharma initiated with a Market Perform at William Blair
- Zealand Pharma price target lowered to DKK 1,050 from DKK 1,080 at Berenberg
- Zealand Pharma’s Earnings Call: Clinical Gains and Challenges